Pep IQ
← Pep IQ
Animal studies showed AOD9604 stimulates lipolysis and inhibits lipogenesis in isolated adipocytes (Heffernan et al. 2001) — a real mechanism on the bench. The fragment corresponds to amino acids 176–191 of human growth hormone, designed to capture the lipolytic activity without the growth-promoting effects of full-length GH.
Community protocols typically use 300–500 mcg SubQ daily for 8–12 weeks, often stacked with other compounds for body recomposition. Higher doses (up to 1 mg) appear in some protocols. The honest read is that community results are highly inconsistent — many users report no measurable fat loss, which aligns with the Phase 2b data rather than contradicting it.
Two Phase 2b trials completed by Metabolic Pharmaceuticals (~300 obese adults, oral, 12 weeks at 1–30 mg). Results: 2.0–2.8 kg additional fat loss vs placebo — statistically significant but modest. The 1 mg dose performed best (counterintuitively). Food intake unchanged, confirming direct fat-mobilisation mechanism. No serious adverse events. But the effect size was insufficient for drug registration — Metabolic Pharmaceuticals did not pursue Phase 3 trials, the program was abandoned for obesity, and the company pivoted to other indications. By comparison: orlistat produces ~3–4 kg more vs placebo over 12 weeks; GLP-1 agonists produce 8–15 kg.
Not FDA-approved. WADA-banned for tested athletes. Status is unusual — recognised as safe (excellent safety data across two Phase 2b trials) but with insufficient efficacy for pharmaceutical approval.
AOD9604 has clean safety data and a real mechanism, but the human trial evidence directly contradicts the marketing as a fat-loss compound. Phase 2b showed only 2–3 kg additional fat loss over 12 weeks at the best-performing dose — the program was abandoned because that magnitude doesn't justify a drug. Pep IQ flags this honestly: there are far better-evidenced options for body composition. AOD9604 is being sold with claims its own clinical trials did not support.
Growth hormone does many things. It promotes growth, it stimulates IGF-1 production, and it burns fat — but these functions are carried by different regions of the GH molecule. Researchers at Monash University in Australia identified in the early 1990s that the C-terminal region of HGH (amino acids 176–191) was primarily responsible for the lipolytic (fat-burning) activity, largely independent of the growth-promoting and insulin-disrupting pathways.
Metabolic Pharmaceuticals took this fragment and added a tyrosine residue at the N-terminus to improve stability, creating AOD-9604 — a 16 amino acid peptide that doesn't bind the GH receptor, doesn't raise IGF-1, and doesn't impair glucose metabolism. The concept was elegant: all the fat burning of GH, none of the hormonal downsides.
The animal data was genuinely impressive. The human trial was not. After a phase 2b trial in roughly 300 obese patients failed to show statistically significant weight loss compared to placebo, Metabolic Pharmaceuticals abandoned the obesity indication in 2007. They subsequently pivoted, licensing AOD-9604 for intra-articular injection in osteoarthritis — an entirely different application. The fat-loss indication has never been re-pursued in a major clinical trial.
The gap most promotional materials skip: AOD-9604 had a Phase 2b human clinical trial for obesity — and it failed. This is a critical fact that is absent from most community discussions of the peptide. The compound is described as having "clinical human data" — which is true. What is less often noted is that the primary endpoint of that clinical data was not met. The 1.8 kg average weight loss over the trial versus placebo was real but not clinically meaningful by pharmaceutical standards. Development was abandoned.
AOD-9604's mechanism is well-characterised at the molecular level and is the genuinely interesting part of its story. Understanding it helps explain both why it works in animals and why the human translation was disappointing.
Why did it fail in humans when it worked in mice? The honest answer is that obesity is metabolically very different between species, beta-3-AR biology differs substantially between mice and humans (humans have far fewer functional beta-3 receptors in brown adipose tissue), and the effect size in animal models — while dramatic — may simply not scale to meaningful human fat loss at safe doses. This is a recurring pattern in metabolic research: rodent fat metabolism does not map to human fat metabolism as cleanly as hoped.